Orion Biotechnology
Phase 1/2Orion is developing two candidates against GPR75, a novel obesity target. Both assets have consistently demonstrated efficacy in preclinical evaluations, and we look forward to advancing these programs into clinical development.
Founded
2016
Focus
Biologics
About
Orion is developing two candidates against GPR75, a novel obesity target. Both assets have consistently demonstrated efficacy in preclinical evaluations, and we look forward to advancing these programs into clinical development.
Funding History
2Total raised: $18M
Series A$15MGimvOct 15, 2021
Seed$3MUndisclosedJun 15, 2019
Company Info
TypePrivate
Founded2016
LocationBasel, Switzerland
StagePhase 1/2
Contact
Sectors
SIMILAR COMPANIES
3Brain
Pre-clinical · Zug
Baxiva
Pre-clinical · Zug
AC Bioscience
Pre-clinical · Lausanne
Abrinca Genomics
Pre-clinical · Zurich
AdipoGen
Pre-clinical · Liestal
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile